The evaluation of XXXX in the treatment of @entity101 complicating pregnancy.

@entity1 @entity644 @entity851 @entity101 @entity6555 @entity600 @entity551
1 Eighty-five @entity1 with severe @entity101 complicating pregnancy were treated with oral @entity6555 ( @entity6555 ). Six of these had a twin pregnancy and 54 had @entity644 . 2 Effective control of the blood pressure was achieved in all but six @entity1 . The maximum dose of @entity6555 prescribed was 1200 mg daily. There were no significant maternal or foetal side-effects. 3 Foeto-placental function was carefully monitored in all @entity1 . Twenty-four of the 89 @entity1 born alive showed evidence of intra-uterine @entity851 , the highest incidence occurring in the group of @entity1 with essential @entity101 complicated by pregnancy induced @entity101 . 4 The low perinatal mortality of 4.4% was a reflection of the meticulous control of the blood pressure. 5 There were no @entity600 or evidence of oculotoxicity in any of the @entity1 delivered. 6 The efficient @entity551 action of orally administered @entity6555 together with the absence of maternal and foetal side effects and consequent improved perinatal mortality confirms that it is an eminently suitable drug for the treatment of @entity101 complicating pregnancy.
